From: Emerging roles of m6A RNA modification in cancer therapeutic resistance
Drug | Regulator | Role | Level | Cancer | Target | Effect | References | |
---|---|---|---|---|---|---|---|---|
Cisplatin | METTL3 | Oncogene | High | NSCLC | AKT1 | enhances expression of AKT1 | [35] | |
Cisplatin | METTL3 | Oncogene | NA | NSCLC | miR-486 | promotes the maturation of pri-miR-486 | [36] | |
Cisplatin | METTL3 | Suppressor | Low | NSCLC | FSP1 | enhances expression of FSP1 | [37] | |
Cisplatin | YTHDF1 | Suppressor | Low | NSCLC | KEAP1 | Promotes transcription of KEAP1 | [38] | |
Cisplatin | METTL3 | Oncogene | NA | GC | ARHGAP5 | Facilitates translation of ARHGAP5 | [39] | |
Oxaliplatin | METTL3 | Oncogene | High | GC | PARP1 | stabilizes PARP1 mRNA via YTHDF1 | [12] | |
Cisplatin | YTHDF2 | Oncogene | NA | GC | CBS | Promotes degradation of CBS mRNA | [40] | |
Cisplatin | METTL14 | Oncogene | NA | GC | c-Myc | stabilizes c-Myc mRNA via a potential reader, MSI2 | ||
Oxaliplatin | METTL3 | Oncogene | High | CRC | CBX8 | stabilizes CBX8 mRNA via IGF2BP1 | [43] | |
Oxaliplatin | METTL3 | Oncogene | High | CRC | TRAF | Promotes TRAF mRNA degradation | [44] | |
Cisplatin | YTHDF1 | Oncogene | High | CRC | GLS1 | promoted translation of GLS1 | [45] | |
Oxaliplatin | YTHDF3 | Oncogene | High | CRC | ATP7A, DYRK1B | promotes translation of ATP7A and DYRK1B | [46] | |
Cisplatin | ALKBH5 | Oncogene | High | EOC | JAK2 | Promotes expression of JAK2 | [47] | |
Cisplatin | YTHDF1 | Oncogene | NA | OC | TRIM29 | Promotes translation of TRIM29 | [48] | |
Cisplatin | METTL3 | Oncogene | High | Seminoma | TFAP2C | increased expression of TFAP2C via IGF2BP1 | [49] | |
Cisplatin | METTL3 | Oncogene | High | Seminoma | ATG5 | Enhances expression of ATG5 | [13] | |
Cisplatin | ALKBH5 | Oncogene | High | OSCC | FOXM1, NANOG | Promotes expression of FOXM1 and NANOG | [50] | |
Cisplatin | FTO | Oncogene | High | OSCC | / | / | [51] | |
Cisplatin | METTL3 | Oncogene | High | NPC | TRIM11 | Stabilizes TRIM11 via IGF2BP2 | [14] | |
Cisplatin | WTAP | Oncogene | High | NKTCL | TNFAIP3 | Stabilizing TNFAIP3 mRNA | [52] | |
Cisplatin | WTAP | Oncogene | High | NKTCL | DUSP6 | Increases stability of DUSP6 mRNA | [53] | |
Cisplatin | VIRMA | Oncogene | High | GCT | XLF, MRE11 | Enhances expression of XLF and MRE11 | [54] | |
Temozolomide | METTL3 | Oncogene | High | GBM | MGMT and ANPG | Increases expression of MGMT and ANPG | [55] | |
Temozolomide | FTO | Oncogene | NA | GBM | PDK1 | Reduces degradation of PDK1 mRNA | [56] | |
Temozolomide | ALKBH5 | Oncogene | High | GBM | NANOG | Reduces degradation of NANOG mRNA | [57] | |
Gemcitabine | METTL3 | Suppressor | Low | PC | lncRNA DBH-AS1 | Promotes DBH-AS1 RNA stability | [58] | |
Gemcitabine | METTL14 | Oncogene | High | PC | CDA | Stabilizes CDA mRNA | [59] | |
Gemcitabine | ALKBH5 | Suppressor | Low | PDAC | WIF-1 | Promotes transcription of WIF-1 | [60] | |
Gemcitabine | SRSF3 | Oncogene | High | PC | lncRNA ANRIL | Regulates alternative splicing ANRIL to increase the ANRIL-L isoform | [61] | |
5-Fluorouracil | METTL3 | Oncogene | High | CRC | miR181b5p | Promotes the miR181b5p process by DGCR8 | [62] | |
5-Fluorouracil | METTL3 | Oncogene | High | CRC | LBX2-AS1 | Stabilizes LBX2-AS1 via IGF2BP1 | [63] | |
5-Fluorouracil | METTL3 | Oncogene | High | CRC | SEC62 | Promotes expression of SEC62 | [64] | |
5-Fluorouracil | METTL3 | Oncogene | High | CRC | P53 | Promotes preferential splicing of p53 pre-mRNA, inducing p53 R273H mutant protein | [65] | |
Doxorubicin | METTL3 | Oncogene | High | BC | MALAT1 | METTL3 promotes MALAT1 expression level | [66] | |
Doxorubicin | METTL3 | Oncogene | High | BC | miR-221-3p | Promotes process of miR-221-3p | [67] | |
Doxorubicin | METTL3 | Oncogene | High | BC | ERRγ | Promotes expression of ERRγ | [68] | |
Doxorubicin | WTAP | Oncogene | High | BC | DLGAP1-AS1 | Increases the stability of DLGAP1-AS1 | [69] | |
Doxorubicin Cisplatin, Olaparib | YTHDF1 | Oncogene | NA | BC | E2F8 | YTHDF1 enhances the E2F8 mRNA stability | [70] | |
Doxorubicin | FTO | Oncogene | High | BC | STAT3 | Promotes expression of STAT3 | [71] | |
Doxorubicin | IGF2BP3 | Oncogene | High | CRC | ABCB1 | ABCB1 increases the stability of ABCB1 mRNA | [72] | |
Doxorubicin, Methotrexate | METTL3 | Suppressor | Low | OS | TRIM7 | Promotes degradation of TRIM7 via YTHDF2 | [73] | |
Doxorubicin | METTL3 | Oncogene | High | CML | PTEN | Promotes degradation of TRIM7 via PTEN | [74] | |
Bortezomib, Melphalan, Carfilzomib | METTL7A | Oncogene | NA | MM | LOC606724 and SNHG1 | promotes enrichment of lncRNAs into exsomes | [75] | |
Arabinocytosine | METTL3 | Oncogene | High | AML | MYC | Increases expression of MYC | [76] | |
Penicillin, Streptomycin | METTL3 | Suppressor | Low | AML | AKT | Decreases expression of AKT | [77] | |
Dexamethasone | ALKBH5 | Oncogene | NA | T-ALL | USP1 | Increasing stability of USP1 mRNA | [78] |